Innovent’s Psoriasis Drug Application Accepted in China
Company Announcements

Innovent’s Psoriasis Drug Application Accepted in China

Innovent Biologics (HK:1801) has released an update.

Innovent Biologics has announced that China’s National Medical Products Administration (NMPA) accepted the New Drug Application for picankibart, a treatment for moderate to severe plaque psoriasis. The drug, an IL-23p19 antibody, demonstrated high efficacy and safety in Phase 3 trials, with promising results such as over 80% of subjects achieving significant skin lesion clearance. Picankibart is poised to improve treatment convenience and quality of life for patients, backed by Innovent’s commitment to meet regulatory standards for a better treatment option in China.

For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskInnovent Biologics Ends Proposed Subscription Agreement
TipRanks HongKong Auto-Generated NewsdeskInnovent Biologics Reports Strong Revenue Growth in Q3 2024
TheFlyInnovent Biologics says picankibart phase 2 study met primary endpoint
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App